CurrentCignaPolicy 0507

Autologous Platelet-Derived Growth Factors (Platelet-Rich Plasma [PRP])

Defines Cigna's coverage stance for autologous platelet-derived growth factors (PRP/APDGF) across multiple indications and describes coding and background; applies to services administered under Cigna benefit plans.

Policy Summary

PayerCigna

PolicyAutologous Platelet-Derived Growth Factors (Platelet-Rich Plasma [PRP])

Policy CodePolicy 0507

Change TypeAnnual review — no clinical changes

Effective DateOct 15, 2025

Next Review DateOct 15, 2026

Key ActionPrior authorization should require documentation of indication, prior conservative care, and PRP protocol details.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

0232T, G0460Codes listed as experimental

InsufficientEvidence statement

510(k)FDA clearance

No changeSummary of changes

Coverage Criteria for Autologous Platelet-Derived Growth Factors (PRP)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Experimental/Investigational/Unproven Indications

Use of autologous platelet-derived growth factors (CPT 0232T; HCPCS G0460) is considered experimental, investigational, or unproven for the following specific indications:

Listed indications considered unproven: anterior cruciate ligament (ACL) repair; bone graft supplementation, regeneration, substitution and/or healing (e.g., lumbar fusion, iliac crest bone graft to maxilla); degenerative joint disease; epicondylitis; epithelial defects of the cornea, persistent; fractures, including long-bone nonunion; joint capsular injuries; muscle injuries and disorders; osteoarthritis of the knee; periodontal disease, gingival recession and dental surgery; plantar fasciitis; sinus augmentation procedures; soft tissue trauma (e.g., tendon and ligament ruptures); total knee arthroplasty; tendonitis; wound healing (e.g., surgical wounds; chronic wounds; lower extremity ulcers); and other indications listed in the policy.

Codes: CPT 0232T; HCPCS G0460

Overall coverage synthesis (evidence-limited)

Coverage considerations are limited by heterogeneous evidence; the document emphasizes limitations that prevent firm, generalized coverage conclusions.

Evidence limitations: Heterogeneity of PRP preparation, dosing, frequency, outcome measures, and short follow-up limit ability to establish consistent benefit or standardized protocols.

Supported across multiple systematic reviews and meta-analyses

Indication-specific signals: Some randomized trials and meta-analyses report short- to mid-term improvements for select indications (e.g., certain knee OA endpoints, plantar fasciitis, lateral epicondylitis) but effects are inconsistent across studies and timepoints.

See individual indication summaries

Recommendation implication: Because of inconsistent results and lack of standardized PRP protocols, the evidence does not uniformly support broad coverage as a standard non-surgical intervention; use should be considered investigational/unproven or covered only under strict, institution-specific criteria or protocols pending higher-quality evidence.

Authors call for well-designed RCTs and standardized protocols

Coverage considerations by indication

Evidence-summary based coverage considerations (items below reflect findings in the cited literature portion):

Knee cartilage degenerative pathology: PRP demonstrated variable efficacy up to 12 months with results dependent on severity; many trials were low quality with heterogeneity in preparation and dosing, limiting generalizable benefit.

Chang et al. (2014) systematic review; follow-up typically ≤12 months

Plantar fasciitis: PRP was not consistently superior to corticosteroids in the short term but some meta-analyses report greater pain and functional improvement in the medium term (≈3–6 months); heterogeneity and lack of standardized protocols limit firm conclusions.failure of ≥3 months conservative therapy in most included studies

Zuo et al. meta-analysis; see individual trials

Rotator cuff repair (surgical adjunct): Leukocyte-poor PRP reduced tendon retear rates (large relative reduction) but observed improvements in pain and function did not reach minimal clinically important differences; structural benefits may not translate to meaningful patient-reported gains.minimum 12-month follow-up used in meta-analyses

Hovland et al.; Chen et al.

Tendon disorders and tendinopathy: Multiple high-quality reviews report no consistent clinically important benefit of PRP over placebo, corticosteroid, or other comparators for many tendinopathies (e.g., lateral elbow, Achilles, patellar); some isolated trials suggest benefit but overall evidence is heterogeneous and low quality.

Franchini et al.; Cochrane/other reviews

Long-bone union/nonunion: When combined with autologous bone graft, PRP did not consistently increase radiographic healing rates or limb function though some analyses reported shorter healing times; evidence is limited and heterogeneous.

Meta-analyses with mixed results

Dental/oral surgery: Autologous platelet concentrates as adjuncts may improve short-term soft tissue healing and early bone density after tooth extraction or augmentation, but studies are small and heterogeneous, limiting definitive conclusions.

Del Fabbro et al.

Total knee arthroplasty: PRP has been associated with decreased perioperative blood loss and shorter hospital stay in some meta-analyses but not with consistent improvements in pain, function, ROM, transfusion rates, or complications; small study numbers and heterogeneity limit conclusions.

Ma et al., Li et al., Kuang et al.

Evidence summaries by indication

Evidence-based findings by indication or setting (presented as conclusions from systematic reviews and trials):

Tooth extraction: Some RCTs report improved short-term soft-tissue healing and early bone density with autologous platelet concentrates, but bone metabolism and complication rates are similar to controls and results are heterogeneous.

Del Fabbro et al.; small, heterogeneous studies

Total knee arthroplasty (TKA): Meta-analyses report decreased total blood loss, smaller immediate hemoglobin drop, and decreased length of stay with PRP in some studies, but no consistent benefit for ROM, pain scores, WOMAC, transfusion rate, or complications; overall heterogeneity and limited trial sizes preclude firm conclusions.

Ma et al., Li et al., Kuang et al.

Wound healing (diabetic foot and chronic wounds): Evidence is mixed: some systematic reviews and RCTs suggest increased complete wound closure and shorter time to healing for diabetic foot ulcers, whereas evidence for venous and pressure ulcers is insufficient or inconsistent.

Qu et al.; mixed results across ulcer types

Musculoskeletal soft tissue/orthopedic injuries: Multiple RCTs and systematic reviews report conflicting results for tendinopathies, rotator cuff pathology, plantar fasciitis, ACL, and other orthopedic indications; overall evidence is insufficient to support routine use across these conditions.

WSHCA technology assessments; systematic reviews

Guideline positions and recommendations

Guideline and coverage positions summarized

AAOS/Professional Society Findings: AAOS: unable to recommend for or against PRP for knee osteoarthritis (2013) and downgraded recommendation to limited in 2021 due to inconsistent evidence; professional statements call for comprehensive PRP characterization and standardized protocols.

AAOS statements on nomenclature, classification, and reporting

VA/DoD Guidance: VA/DoD (2020): insufficient evidence to recommend for or against PRP injections for hip or knee osteoarthritis.

VA/DoD clinical practice guidelines

Wound Healing Society: systematic reviews and RCTs did not demonstrate increased healing rates for diabetic foot ulcers with PRP.

Wound Healing Society guidance

Professional recommendations on standardization: Consensus recommendations emphasize the need for an accepted PRP nomenclature/classification, establishment of the influence of donor/processing/delivery on PRP composition, validated efficacy assays per indication, and minimum reporting standards for PRP studies.

AAOS and other professional recommendations

The policy states that the use of autologous platelet‑derived growth factors (APDGF/platelet‑rich plasma; CPT 0232T; HCPCS G0460) for any condition or indication is considered experimental, investigational, or unproven. The policy lists multiple specific examples of such indications, including but not limited to anterior cruciate ligament repair, bone graft supplementation/healing, degenerative joint disease, epicondylitis, osteoarthritis of the knee, plantar fasciitis, tendon injuries, total knee arthroplasty, and wound healing.

Because these uses are classified as experimental/investigational/unproven under the policy, services billed using the listed codes for these indications are not supported as covered benefits under standard Cigna plans.

Systematic reviews of intra‑articular PRP for hip osteoarthritis have not demonstrated clear superiority over saline or other comparators through approximately six months of follow‑up. One pooled review of randomized trials found no intervention, including PRP, showed statistically significant improvement versus saline at 2–4 and six months for pain or functional outcomes, and study limitations included heterogeneity and short‑term follow‑up. Given these findings, PRP for hip intra‑articular injection lacks demonstrated short‑term benefit in the included studies.

Multiple high‑quality reviews and meta‑analyses evaluating chronic tendinopathies (e.g., lateral elbow epicondylitis, Achilles tendinopathy, patellar tendinopathy) report inconsistent or no clinically meaningful benefit of PRP compared with placebo, corticosteroid, or other comparators. Cochrane and other systematic reviews concluded there is no clear indication supported for routine PRP use in many tendinopathies because of heterogeneous methods, variable comparators, and generally low‑quality evidence.

Because the evidence for chronic tendinopathies is mixed and often negative, PRP for these indications is not supported as a consistently effective therapy in the reviewed literature.

PRP preparations are not standardized across studies, and although devices used to prepare PRP are commonly cleared through FDA 510(k) pathways, PRP products themselves are generally not FDA‑indicated for direct injection. The technology assessments and professional society statements note wide variability in PRP preparation methods (centrifugation, leukocyte content, activators), which prevents direct comparison of study results and contributes to uncertainty about safety and effectiveness for specific applications.

This lack of standardization and absence of FDA indication for PRP formulations used for injection are cited as important limitations when evaluating clinical evidence and coverage decisions.

Professional guidelines reiterate the current evidence uncertainty for PRP. The AAOS has stated it cannot recommend for or against PRP for knee or glenohumeral osteoarthritis and in 2021 downgraded its recommendation to limited because of inconsistent evidence, emphasizing the need for comprehensive PRP characterization and standardized reporting. The VA/DoD clinical practice guideline (2020) similarly concluded there is insufficient evidence to recommend for or against PRP injections for hip or knee osteoarthritis. The Wound Healing Society reported that PRP has not demonstrated an increased healing rate for diabetic foot ulcers based on systematic review and randomized trials.

The policy underwent routine annual review and the documentation notes no changes to the clinical policy statement. This administrative update did not alter the policy’s coverage stance that PRP/APDGF uses are considered experimental, investigational, or unproven.

Consistent with the policy’s overall coverage position, the use of autologous platelet‑derived growth factors (PRP/APDGF) for the indications listed in the policy is explicitly identified as experimental, investigational, or unproven and therefore not supported as a covered benefit under this policy. The policy’s listing of CPT code 0232T and HCPCS code G0460 reinforces that these services, when provided for the enumerated indications, are considered not covered.

Given the heterogeneity of PRP preparations, inconsistent study results, and generally short follow‑up in many trials, the policy interpretation recommends against routine use of PRP for knee osteoarthritis and other musculoskeletal indications as a standard therapy. The policy highlights that apparent short‑term or mid‑term benefits reported in some studies do not overcome the broader evidence limitations, and routine coverage is not supported without well‑designed, standardized trials demonstrating durable clinical benefit.

The evidence summarized for chronic tendinopathy and several orthopedic indications shows mixed or negative results: meta‑analyses and systematic reviews frequently report no significant advantage of PRP over comparators or placebo for many tendon disorders. Where some individual studies or subsets 'seemed' to show benefit (for example, patellar or lateral elbow in limited analyses), the overall quality, heterogeneity, and short‑term follow‑up of the body of evidence prevent a conclusion of effectiveness for routine clinical use.

For knee and hip osteoarthritis and numerous musculoskeletal conditions, technology assessments and systematic reviews conclude that PRP is unproven to be safer, more effective, or more cost‑effective than comparator treatments. The Washington State Health Care Authority re‑review (2023) and earlier technology assessments found insufficient, low‑quality, or conflicting evidence across these indications, supporting the policy’s stance that PRP applications in these settings are not established therapies.

The Wound Healing Society and related systematic reviews did not find consistent evidence that PRP increases the healing rate or number of healed wounds for diabetic foot ulcers. The guideline assessments and randomized trials cited in the policy indicate no demonstrated improvement in wound healing outcomes with PRP for these chronic wound indications.

The provided excerpt does not list explicit procedural or diagnosis exclusions beyond the policy’s classification of PRP/APDGF uses as experimental/investigational/unproven. The annual review entries reiterate that there were no clinical policy statement changes during the review period.

Coding and Billing for PRP/APDGF

Considered Experimental/Investigational/UnprovenCPTNot Covered

0232T

Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed

Considered Experimental/Investigational/UnprovenHCPCSNot Covered

G0460

Autologous platelet rich plasma (PRP) or other blood-derived product for nondiabetic chronic wounds/ulcers (includes, as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment)

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior authorization for mixed‑evidence indications

Prior authorization recommended for mixed-evidence indications (e.g., plantar fasciitis) due to limited, inconsistent, or medium‑term benefit evidence. Review clinical indication, documentation of prior conservative care, and expected benefit timeframe when submitting requests.

Example mixed‑evidence indications: plantar fasciitis, select tendinopathies, some nonoperative musculoskeletal uses

Prior Authorization

Prior authorization likely required — confirm PRP formulation and protocol

Prior authorization likely required for many PRP uses because of lack of standardized formulations and protocols. Verify indication details, PRP formulation (e.g., leukocyte‑rich vs leukocyte‑poor), preparation method, injection protocol, number/timing of injections, and intended clinical goals.

Confirm PRP formulation (LR‑PRP vs LP‑PRP)
Provide preparation method and device used
Specify injection technique, volume, frequency, and total planned treatments

Prior Authorization

Medicare NCD/LCD — verify coverage with applicable Medicare determinations

Verify applicable Medicare national and local coverage determinations before approving or denying PRP for wound or other indications. NCD 270.3 (Blood‑Derived Products for Chronic Non‑Healing Wounds) and LCD L36690 (Wound Application of Cellular and/or Tissue Based Products, Lower Extremities) may affect coverage decisions.

NCD 270.3 — Blood‑Derived Products for Chronic Non‑Healing Wounds (rev effective 4/13/2021)
LCD L36690 — Wound Application of CTPs, Lower Extremities (rev effective 9/4/2025)
Review current Medicare policy for updates

Denial Risk

Evidence uncertainty may trigger denial

Evidence uncertainty, heterogeneity of study results, and lack of long‑term data may trigger denial of coverage when documentation does not establish medical necessity or expected benefit for the specific member and indication.

Heterogeneous, low‑quality studies and short follow‑up reported across indications
Lack of standardized PRP protocols and unclear duration of benefit

Denial Risk

Evidence limitations may trigger noncoverage

Limitations in the evidence base — including small sample sizes, high risk of bias, inconsistent outcome measures, and short follow‑up — are reasons services may be considered not covered or investigational for a given indication.

Common study limitations: small populations, inconsistent PRP prep, short follow‑up
Conflicting results across systematic reviews/meta‑analyses

Denial Risk

Insufficient evidence may trigger denial

Insufficient or low‑quality evidence for many indications (e.g., several musculoskeletal and wound uses) may result in denial when claims lack supportive, indication‑specific documentation demonstrating expected clinical benefit.

PRP safety/efficacy not well established for many orthopedic and soft‑tissue conditions
Committee and technology assessments found evidence insufficient or unproven

Denial Risk

Medicare coverage considerations may trigger denial

Medicare coverage considerations may trigger denial — consult NCD/LCD before authorization and document how the request aligns with any Medicare coverage criteria or, if not covered by Medicare, provide rationale for medical necessity under the member's plan.

Check NCD 270.3 and LCD L36690 prior to decision
Document comparison to Medicare criteria when applicable

Documentation Required

Required documentation to support medical necessity

Required documentation to support medical necessity: include the specific diagnosis, duration and details of prior conservative treatments and their failure or intolerance, objective findings, and planned PRP procedure details.

Diagnosis and clinical history
Details and duration of conservative care (e.g., physical therapy, NSAIDs, orthotics) and why alternatives failed — e.g., plantar fasciitis ≥3 months of conservative care
Objective imaging or exam findings supporting the indication

Documentation Required

Required documentation elements (suggested by evidence gaps)

Required documentation elements suggested by evidence gaps: document prior therapy duration (for example, ≥3 months for plantar fasciitis), specifics of failed/contraindicated treatments, functional impact, and expected timeframe of benefit to justify PRP use.

Duration of prior conservative therapy with dates and outcomes
Functional scales or pain scores pre‑treatment (e.g., VAS, WOMAC, AOFAS)
Rationale for PRP vs alternatives and expected outcome timeline

Documentation Required

Need PRP characterization details

Document the PRP characterization and preparation details due to lack of standardization: include measured platelet concentration, leukocyte content, use of activator, centrifugation protocol, device/manufacturer, and lot numbers when available.

Measured characteristics: platelet count/concentration, leukocyte presence/absence
Preparation protocol: centrifugation steps, volume collected, activator used
Device/manufacturer and any assay results

Note

Document notes annual review and policy status

Administrative note: annual review performed. Maintain documentation of any policy‑level updates and clinical rationale; clinical policy statements indicated no changes on recent annual reviews (see revision history).

Annual review dates noted (e.g., 10/15/2023–10/15/2025)
Record of 'No clinical policy statement changes' for referenced reviews

Step Therapy

Step therapy before PRP — step‑therapy considerations

Step‑therapy considerations: consider requiring failure or intolerance of appropriate standard noninvasive therapies (e.g., physical therapy, NSAIDs, activity modification, orthoses) before approving PRP for many musculoskeletal indications.

Examples of conservative therapies: structured PT program, night splints/orthoses, NSAIDs, corticosteroid trial when appropriate
Document duration and response to each conservative modality

Note

No step therapy requirements specified in excerpt

No specific step‑therapy requirements were specified in the provided policy excerpt. When absent, follow the plan's general medical necessity rules and any client‑specific delegated protocols.

If the benefit plan lacks explicit step therapy, document clinical rationale and prior treatments when requesting PRP authorization

Background on PRP / APDGF

Platelet‑rich plasma (PRP), also described in the policy as autologous platelet‑derived growth factors (APDGF), is an autologous blood‑derived product concentrated for platelets and platelet growth factors and proposed to enhance healing across wound, orthopedic, dental, and surgical indications. The policy frames PRP/APDGF as a biologic modality with wide variation in preparation methods and compositions, which contributes to heterogeneity in clinical study results and uncertainty regarding consistent clinical effectiveness.

Definitions and Terminology

PRP/APDGF definition

DefinitionPlatelet-rich plasma (PRP)/autologous platelet-derived growth factors (APDGF) — an autologous blood–derived product prepared from the patient’s own blood using collection and preparation systems to concentrate platelets and growth factors for application (e.g., gel or injectable).

Source material and systemsPrepared at point-of-care or clinical lab using FDA 510(k)-cleared collection/preparation systems (examples: Arthrex ACP, GPS III, PurePRP SupraPhysiologic, SmartPReP 2 APC+).

Proposed mechanismProvides concentrated growth factors (e.g., tissue growth factor, platelet-derived growth factors) proposed to mediate mesenchymal stem cell proliferation and increase matrix synthesis and collagen formation.

Clinical contexts describedProposed uses include wound care, orthopedic conditions, oral/dental procedures, and as an additive to other injectables (e.g., with mesenchymal stem cells).

Evidence summary statementThe document states there is insufficient evidence to support use of PRP/APDGF for any indication due to heterogeneity and low-quality data.

Autologous platelet-derived growth factor (APDGF) / PRP

DefinitionAutologous platelet-derived growth factor (APDGF)/PRP — a blood-derived concentration of platelets and platelet growth factors administered peritendinously or intra-articularly, prepared variably across trials (different centrifugation methods, leukocyte content, use of activators).

Administration routesDescribed routes include peritendinous injections (tendinopathies) and intra-articular injections (osteoarthritis).

Protocol variabilityStudies vary in number of injections, dose/volume, intervals, preparation devices, and use of exogenous activators, contributing to heterogeneity in outcomes.

Clinical trial contextIncluded RCTs compare APDGF/PRP to comparators such as corticosteroid, hyaluronic acid, saline, ozone, or placebo with follow-up periods ranging from weeks to 12+ months.

Leukocyte-poor PRP (LP-PRP)

DefinitionLeukocyte-poor PRP (LP-PRP) — a PRP preparation characterized by low leukocyte content used in randomized trials for rotator cuff repair and analyzed separately in meta-analyses.

Findings in rotator cuff trialsLP-PRP applied at the bone-tendon interface showed a statistically significant 46% relative reduction in retear rates in a meta-analysis of RCTs, though functional/pain improvements did not meet MCID.

Limitations notedMeta-analysis limitations include small sample sizes, lack of standardization of PRP preparation, underreporting of platelet/cytokine concentrations, and absence of sex-disaggregated outcomes.

Autologous platelet concentrates (APC)

DefinitionAutologous platelet concentrates (APC) — a group term that includes PRP and related platelet-derived products used as adjuncts in periodontal and oral surgery and other dental procedures.

Efficacy signalsCochrane review found very low-quality evidence of some improvements in probing depth, clinical attachment level, and radiographic defect filling for APC used with open flap debridement and with bone grafting in infrabony defects.

Evidence limitationsOverall evidence is heterogeneous, often small studies with high risk of bias and imprecision, limiting firm conclusions about benefit.

Platelet-rich plasma (PRP)

DefinitionPlatelet-rich plasma (PRP) — an autologous blood concentrate with increased platelet concentration; preparation methods, platelet/cytokine composition, and application techniques vary widely across studies.

Preparation variabilityPRP is produced using different collection/preparation systems and protocols (centrifugation, activation), leading to variable platelet concentrations and compositions.

Regulatory pointPreparation systems are generally cleared via FDA 510(k) for preparing autologous PRP from a patient’s blood; PRP products themselves are not standardized or FDA-indicated as specific injectable products.

Minimum standards of reporting for PRP studies

Minimum reporting standards (recommended)Professional societies call for minimum standards of reporting for PRP studies, including measured characteristics of the PRP and factors relating to donor, processing, and delivery.

Specific recommended elementsStandards should include an accepted nomenclature/classification, measured platelet and cytokine concentrations, donor/processing/delivery factors, and protocol details (volume, activation, timing).

PurposeThese standards are intended to facilitate comparison across studies, establish relationships between PRP composition and efficacy, and support proof of safety and efficacy for specific indications.

Definitions (placeholder)

PlaceholderNo definition content provided in source for this inventory item (empty).

ReferencesReferences and bibliography are present in the source but do not supply a definition for this item.

ActionNo additional definitional text available in the document excerpt.

Policy Revision History

2025-10-15annual_reviewLatest

Annual review conducted; no clinical policy statement changes noted (administrative/template updates previously in 2023).

2024-10-15annual_review

Annual review conducted; no clinical policy statement changes noted.

2023-10-15administrative_update

Updated to new template and formatting standards; no changes to clinical criteria.

Policy Summary

PayerCigna

PolicyAutologous Platelet-Derived Growth Factors (Platelet-Rich Plasma [PRP])

Policy CodePolicy 0507

Change TypeAnnual review — no clinical changes

Effective DateOct 15, 2025

Next Review DateOct 15, 2026

Key ActionPrior authorization should require documentation of indication, prior conservative care, and PRP protocol details.

SourceLink

On This Page